跳至主要内容
临床试验/NCT00151905
NCT00151905已完成2 期

Nebulized Hypertonic Saline in the Treatment of Bronchiolitis in Infants

Sheikh Khalifa Medical City5 个研究点 分布在 2 个国家开始时间: 2003年11月1日最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
试验地点
5
主要终点
Length of stay.

研究概览

简要总结

Bronchiolitis is a common viral lung infection in infants. Standard treatment often includes the use of inhaled medications which are usually first mixed with a standard salt solution. Inhalation of a more concentrated salt solution (hypertonic saline) has been successfully used to treat other types of lung disease in children and adults. The purpose of this study is to see if using inhaled hypertonic saline helps infants with bronchiolitis get better more quickly.

详细描述

Bronchiolitis is a common illness in infants and is associated with a significant morbidity. Standard therapy is controversial and largely ineffective; care is mostly supportive although nebulized medications continue to be commonly used. These medications are typically mixed with normal saline to produce a sufficient volume for efficient nebulization.

Inhaled hypertonic saline has been used to aid airway clearance in children with cystic fibrosis. It has also been used, in low dose, in two small studies in children with bronchiolitis. The current study is a randomized, double-blind, placebo-controlled, multi-center trial comparing frequent dosing with 3% hypertonic saline compared to normal saline in the treatment of infants hospitalized with bronchiolitis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
— 至 18 Months(Child)
性别
All
接受健康志愿者

入选标准

  • Corrected age maximum 18 months, plus
  • History of preceding viral upper respiratory tract infection, plus
  • Presence of wheezing and/or crackles on auscultation, plus
  • Respiratory Distress Assessment Instrument (RDAI) score of 4 or greater, or oxygen saturation of 93% or less in room air, plus
  • Admitted to hospital

排除标准

  • Prior history of wheezing, or
  • History of chronic cardiopulmonary disease or immunodeficiency, or
  • Critical illness at presentation requiring admission to ICU, or
  • Use of nebulized hypertonic saline within previous 12 hours, or
  • Prematurity (gestational age 34 weeks or less).

结局指标

主要结局

Length of stay.

次要结局

未报告次要终点

研究者

申办方类型
Other

研究点 (5)

Loading locations...

相似试验

The Use of an Inhaled Salt Solution to Treat Viral... | 临床试验